Novo data buttress its oral semaglutide case, this time in kidney-impaired patients

Novo Nordisk
Novo Nordisk's oral semaglutide topped placebo at reducing hbA1c among kidney-impaired patients. (Novo Nordisk)

The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles.

Monday, the Danish drugmaker said that in a phase 3a trial of Type 2 diabetes patients with kidney impairment, the prospect topped placebo at significantly reducing hbA1c, a common blood glucose measure, at week 26. And those in the study’s semaglutide arm recorded larger weight-loss numbers, too.

"Renal impairment is a serious diabetes complication and people with this condition have limited oral anti-diabetic treatment options, and if approved oral semaglutide represents an efficacious new solution for these people," Novo’s chief science officer, Mads Krogsgaard Thomsen, said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Novo Nordisk trumpets more Januvia-topping data for oral semaglutide

The data add to a wealth Novo has already generated for the up-and-comer. In June, the company rolled out favorable results pitting semaglutide against fellow Novo GLP-1 drug Victoza and Merck mammoth Januvia, a DPP-4 therapy.

But all of that clinical evidence will be key for Novo as it pushes its pill into a competitive GLP-1 market, which features stiff competition from Eli Lilly in addition to Novo’s own options. And it’ll no doubt also come into play when Novo sits down to choose a price for semaglutide, a decision that could go a few different ways.

RELATED: Novo has a big pricing decision to make with semaglutide. Which way will it go?

Novo has to “make some technical considerations,” around pricing, CEO Lars Fruergaard Jørgensen said in a recent interview, adding, “Do we price as a GLP-1, or do we price more as a tablet, or somewhere in between?”

Suggested Articles

Bayer Chairman Werner Baumann could face a vote a no confidence from its top investor, BlackRock, Reuters reported.

When Sanofi inked a massive lease in Cambridge Crossing last year, the drugmaker found itself in prime position for another real estate deal.

Amid China's tighter grip on antibiotics use, Lilly sold Chinese rights to two legacy antibiotics and a manufacturing facility to China's Eddingpharm.